2024 ASCO Abstract for Trial #20-13

Investigation of a potential protein biomarker signature that may predict clinical benefit of NT-I7 and pembrolizumab in patients with cold gastrointestinal tumors.

Wednesday, June 19, 2024

Dr. Minal Barve

Read the Story Here

View the abstract via the above link.

ASCO Poster for Trial 20-13

ASCO 2024 Poster for Trial 20-13

Click here to view the ASCO 2024 Poster for Trial 20-13 in Full-Size.

Related Abstracts

Discover more abstracts for our trials.

A biomarker signature differentiates immune status in patients with cold gastrointestinal tumors, predicting clinical benefit of NT-I7 (efineptakin alfa, a long-acting interleukin-7) and pembrolizumab

Dec 17, 2024

Utilizing pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers to support recommended Phase 2 dose (RP2D) selection for Phase 1 study of SAR444245 (SAR’245) in patients with advanced solid tumors

Dec 17, 2024

Trial in progress: A first-in-human phase 1a/b, dose-escalation/expansion study of BG-68501/ETX-197 (CDK2 inhibitor) as monotherapy or in combination with fulvestrant for patients with HR+/HER2− breast cancer and other advanced solid tumors

Dec 17, 2024
See All Posts